GlassScriptPhysician profile
Nasser S Tehrani
NPI 1831185388
$9,633.96
in general payments reported to CMS, 2019-2025
31 companies · $923 in 2025
The $923 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $3,433 · 2021: $442 · 2022: $2,181 · 2023: $1,575 · 2024: $545 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Travel and Lodging: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.46 |
| Travel and Lodging | $749.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,405.52 | 2019-2020 | |
| Medtronic, INC. | $2,103.29 | 2020-2025 | Mycarelink |
| Medical Device Business Services, INC. | $817.35 | 2023 | Carto 3 |
| Cardiovascular Systems INC. | $775.60 | 2019-2020 | |
| Philips North America LLC | $707.88 | 2019-2025 | Ecc Solutions |
| Merck Sharp & Dohme LLC | $374.05 | 2021-2025 | Verquvo, Capvaxive |
| Shockwave Medical, INC | $297.09 | 2025 | |
| Boston Scientific Corporation | $272.54 | 2019-2025 | General - Vascular Access, General - Thrombectomy |
| Esperion Therapeutics, INC. | $226.36 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.65 | 2019-2022 | |
| Abbott Laboratories | $180.52 | 2019-2023 | Diamondback Peripheral, Aveir |
| Abiomed | $172.94 | 2023-2025 | Impella |
| Pfizer INC. | $137.07 | 2022-2025 | |
| Novo Nordisk INC | $127.37 | 2024 | |
| Sanofi-Aventis U.S. LLC | $124.41 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $109.54 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $108.04 | 2023-2025 | |
| Chiesi USA, INC. | $84.01 | 2024-2025 | Kengreal, Cleviprex |
| Janssen Pharmaceuticals, INC | $66.78 | 2019-2024 | Xarelto |
| Amgen INC. | $63.46 | 2022-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $38.47 | 2023 | Onpattro |
| Heartflow, INC. | $37.14 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $36.38 | 2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $34.25 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $27.13 | 2023 | Mounjaro |
| Vital Connect, INC | $25.55 | 2024 | Vitalpatch Rtm |
| Cvrx, INC. | $23.37 | 2024 | Barostim Neo System |
| Penumbra, INC. | $19.72 | 2025 | Indigo System |
| Scpharmaceuticals INC. | $17.95 | 2023 | |
| Cardinal Health 200 LLC | $17.79 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.